TORONTO, ONTARIO–(Marketwired – March 18, 2015) – Arch Biopartners Inc (“Arch”) or the “Company”)(TSX VENTURE:ACH) and (OTCBB:FOIFF) announced today it has identified a new candidate drug to treat Pseudomonas aeruginosa respiratory infections.
Press Releases
Arch Biopartners Announces Issuance of U.S. Patent for Peptide Solid Surface Interface
TORONTO, ONTARIO–(Marketwired – Feb. 25, 2015) – Arch Biopartners Inc (“Arch” or the “Company”) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office has issued U.S. Patent 8,961,984, titled “Surface Coated Structures and Methods” protecting its peptide-solid surface technology which has been shown to reduce biofilm formation, corrosion and friction on various metals and plastics.
Arch Biopartners Receives Final Approval to List on TSX Venture Exchange
TORONTO, ONTARIO–(Marketwired – Feb. 19, 2015) – Arch Biopartners Inc (“Arch” or the “Company”) (CSE:ACH)(OTCBB:FOIFF) has received final approval for its common shares to be listed on the TSX Venture Exchange (TSXV).
Arch Biopartners Completes Private Placement
TORONTO, ONTARIO–(Marketwired – Jan. 26, 2015) – Arch Biopartners Inc (“Arch or the “Company”) (CSE:ACH)(OTCBB:FOIFF) announced today it has raised an additional $90,650 by closing the second tranche of the non-brokered private placement it announced in a press release January 6, 2015.
Arch Biopartners Receives Conditional Approval for Listing on TSXV
TORONTO, ONTARIO–(Marketwired – Jan. 16, 2015) – Arch Biopartners Inc (“Arch”) (CSE:ACH)(OTCBB:FOIFF) has received conditional approval from the TSX Venture Exchange (“TSXV”) for the listing of its common shares on the TSXV.
Arch Biopartners Announces Private Placement
TORONTO, ONTARIO–(Marketwired – Jan. 6, 2015) – Arch Biopartners Inc (“Arch or the “Company”) (CSE:ACH)(OTCBB:FOIFF) intends to complete a non-brokered private placement offering of up to 2,143,000 units priced at $0.35 per unit (the “Units”) for gross proceeds of up to $750,050 (the “Offering”).
Arch Biopartners Completes Clinical Development Plan for MetaMx
TORONTO, ONTARIO–(Marketwired – Nov. 26, 2014) – Arch Biopartners Inc (CSE:ACH)(OTCBB:FOIFF) has now completed a Clinical Development Plan (“CDP”) to prepare a human trial for MetaMx, the Company’s brain tumour targeting technology.
Arch Biopartners Introduces Metablok, a Novel Therapeutic Candidate for Blocking Sepsis, Cancer Metastasis
TORONTO, ONTARIO–(Marketwired – Oct. 15, 2014) – Arch Biopartners Inc (“Arch” or the “Company”) (CSE:ACH)(OTCBB:FOIFF) announced today the introduction of Metablok, a new drug candidate in its development pipeline as a potential treatment for sepsis and cancer metastasis.
Arch Biopartners Appoints Adrian Haigh to Board of Directors
TORONTO, ONTARIO–(Marketwired – Aug. 21, 2014) – Arch Biopartners Inc (“Arch” or the “Company) (CSE:ACH)(OTCBB:FOIFF) announced today the board has appointed Adrian Haigh as an interim director.
Mr.
Arch Biopartners Hires d3 Medicine to Develop a Human Trial for Brain Tumor Targeting Technology
TORONTO, ONTARIO–(Marketwired – May 29, 2014) – Arch Biopartners Inc (Arch) or (the Company) (CSE:ACH)(OTCBB:FOIFF) announced today it has hired d3 Medicine to work as the Company’s new drug development team.
d3’s first task will be to design a Phase I/II human trial for MetaMx, the Company’s brain tumour targeting technology, in patients with malignant glioma.